AI That Monitors Kidney Function
FIZE Medical has developed a digital patented device for kidney urine output (UO) continuous and real-time monitoring. It synchronizes in real time with the electronic patient record. The patented technology that includes an AI layer, aims to empower healthcare professionals to detect kidney function deterioration early on, enabling timely intervention and personalized treatment.
"The highest patients' death rate – 25% - is found in hospitals' intensive care units (ICUs) . One major contributing factor is renal failure, as it has been notoriously difficult to monitor kidney urine output effectively", so says Dror Zerem, FIZE Medical CEO. FIZE Medical has developed a smart fluid management platform that offers continuous digital monitoring of kidney urine output and synchronizes in real time with the electronic patient medical record. "In fact," he adds, "about 50% of patients hospitalized in intensive care units, without kidney prior complications, will be discharged with kidney damage".
A Persistent Challenge Finally Solved
"Kidney function is one of the last vital sign that is still monitored manually by traditional urinometers, and the medical team is not always able to identify deterioration in real time, without prior warning. Multiple companies have tried to solve this challenge in the last 15 years without success, until entrepreneur Noam Levine, founder of FIZE Medical, came along, and since then everything is history."
Levine identified a critical gap in fluid management: without precise measurement of urine output, the entire fluid management practices are compromised. The challenge was to develop an automated, digital platform that met and exceeded clinical goals.
Why are the kidneys so important?
"The kidneys reflect the body's entire hemodynamic status, integrating data from blood pressure, heart rate, and other vital signs. Even cardiac failure often manifests first through renal deterioration. "
Monitoring of renal fluid balance
FIZE Medical's platform provides continuous monitoring of kidney fluid balance, enabling personalized and adaptive treatment plans. The device captures every drop of urine in the patient's catheter, generating highly accurate data that allows early detection of kidney deterioration. FIZE Medical is also launching an advanced AI layer, designed to support clinical decision-making before patients enter a critical stage where mortality risk significantly increases. "FIZE Medical applies AI tools to patient UO data without patient identification ," explains Zerem. "Up until today, such data did not exist in the medical world. By integrating AI, we can analyze trends much earlier, anticipate patient deterioration, and recommend appropriate interventions in real time. "
A Step-by-Step Approach to Innovation
Rather than waiting years to develop a fully matured product, FIZE Medical follows an step-by-step innovation strategy. The company first introduced its core platform to the market and plans to continuously add new capabilities each year. "Ultimately, our goal is to address one of the greatest ICU challenges—maintaining patient stability—with increasing automation, all while keeping doctors in control," says Zerem. "Our vision is to reach a level of autonomous hemodynamic management, where we help regulate blood pressure, protect the heart and lungs from edema, and preserve kidney function—proactively rather than reactively..
Proven Success in Leading Hospitals
Since entering the Israeli market in September 2023, FIZE Medical has deployed over 100 devices across multiple hospitals, including Soroka Medical Center in Be'er Sheva. The technology is being used in cardiac ICU, neurosurgery, general ICU, cardiothoracic surgery, and pediatric intensive care units.
By the end of 2025, the company expects half of Israel's hospitals to adopt its kidney monitoring platform. The company has also launched operations in the U.S., with dozens of systems already active in leading American hospitals.
Additionally, FIZE Medical has secured a supply agreement and single-supplier status with Clalit Health Services, Israel's largest HMO.
"To date, we have monitored over 4,000 patients, and the numbers speak for themselves. The growing demand from hospitals is proof that our system works—and saves lives," says Zerem. "Some ICUs have even requested additional units due to increased patient volume following the 'Iron Swords' war."
Beyond Kidney Monitoring: The Future of AI-Driven ICU Care
Does your product monitor all hemodynamic function or just renal function?
"Currently, our system focuses on renal monitoring," says Zerem, "but because kidney function provides a real-time reflection of overall patient stability, we are leveraging this capability to improve broader hemodynamic monitoring. Our goal is to optimize treatment plans and reduce the burden on clinicians by making fluid management more autonomous."
Where are you heading next?
"We chose to start in Israel not only because we are an Israeli company, but because Israeli physicians have an outstanding global reputation. After proving the technology in leading hospitals, we are now rapidly expanding internationally."
FIZE Medical
Year of establishment: 2019.
Founder: Noam Levine.
Field of activity: Development of an AI-based platform for monitoring kidney function.
Leading motto: Every drop counts.
In collaboration with FIZE Medical
